The first approval of an ADC for cancer treatment occurred in 2000 when Gentuzumab ozogamicin, an anti-CD33 mAb-calicheamicin conjugate, was introduced for the treatment of relapsed CD33+ acute myeloid leukemia (AML) [7]. Here, CD33 is linked to acute myeloid leukemia.